AS 601811

Drug Profile

AS 601811

Latest Information Update: 12 Mar 2008

Price : $50

At a glance

  • Originator Merck Serono
  • Class
  • Mechanism of Action Cholestenone 5-alpha reductase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • Discontinued Acne; Benign prostatic hyperplasia; Hirsutism; Male pattern baldness; Prostate cancer

Most Recent Events

  • 29 Nov 2004 Suspended - Phase-I for Male pattern baldness in Switzerland (PO)
  • 29 Nov 2004 Suspended - Phase-I for Benign prostatic hyperplasia in Switzerland (PO)
  • 29 Nov 2004 Suspended - Phase-I for Hirsutism in Switzerland (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top